SCHEMBL3530693

SCHEMBL3530693

CN1CCN(CC(=O)N2CCC(c3cccc(N)c3)CC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 2/20 0.48
TLR8 Q9NR97 2/20 0.48
TLR7 Q9NYK1 2/20 0.48
NAMPT P43490 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
TSHR P16473 1/20 0.42
DRD2 P14416 2/20 0.41
FAAH O00519 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
CCR6 P51684 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525695 0.85 TLR9 (0.48) TLR9TLR8TLR7NAMPTKMT2A
SCHEMBL27741867 0.81 TLR9 (0.41) TLR9TLR8TLR7NAMPTKMT2A
SCHEMBL3531340 0.80 TLR9 (0.47) TLR9TLR8TLR7
SCHEMBL328311 0.79 QDPR (0.53) DRD2ADRA2C
SCHEMBL2651932 0.78 QDPR (0.60) ALDH1A1KDM4E
SCHEMBL4771671 0.77 NR1I3 (0.47) TLR9TLR8TLR7NAMPTDRD2
SCHEMBL27741869 0.77 ACHE (0.45) TLR9TLR8TLR7NAMPTKMT2A
SCHEMBL27893011 0.77 DRD2 (0.49) DRD2DRD4DRD3
SCHEMBL4615095 0.76 NPC1 (0.45) FAAHALDH1A1TP53
SCHEMBL2662210 0.75 DRD4 (0.46) DRD2ALDH1A1MAPTHTTDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR TLR9 2412/4885TLR8 1749/4885TLR7 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.